Taylor, M.;
Mealing, S.;
Scott, D.;
Clark, J.;
McKenna, M.;
Lebmeier, M.;
Davis, C.
PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
PSY37 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 600/800mg Daily as Therapy for Imatinib Failing Chronic Myeloid Leukemia (CML)
Contributor:
Taylor, M.;
Mealing, S.;
Scott, D.;
Clark, J.;
McKenna, M.;
Lebmeier, M.;
Davis, C.